Evidence map›Paper›PMID 40599578›Full record

ReviewRSC advances2025

Research progress on the preparation, performance, mechanisms, and applications of carbon nanomaterials against Gram-negative bacteria.

Chengwei Zhang, Ying Zheng, Xiaoyan Lin, Shaohuang Weng

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chengwei ZhangSchool of Basic Medical Sciences, Fujian Medical University Fuzhou 350122 China.ORCID https://orcid.org/0009-0009-1159-3335
Ying ZhengDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University Fuzhou 350122 P. R. China shweng@fjmu.edu.cn.
Xiaoyan LinDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University Fuzhou 350122 P. R. China shweng@fjmu.edu.cn.
Shaohuang WengDepartment of Pharmaceutical Analysis, School of Pharmacy, Fujian Medical University Fuzhou 350122 P. R. China shweng@fjmu.edu.cn.ORCID https://orcid.org/0000-0002-4739-5615

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The excessive and inappropriate use of antibiotics in clinical settings has led to bacterial mutations and the emergence of drug resistance. This escalating problem presents a major challenge in the treatment of infections, particularly those caused by Gram-negative and multidrug-resistant bacteria, for which effective therapeutic options are increasingly limited. As a result, there is an urgent need to develop novel antimicrobial agents. Recent studies have demonstrated that carbon nanomaterials, owing to their potent antibacterial activity and low susceptibility to resistance, are emerging as promising candidates in antimicrobial research. This review provides a comprehensive overview of recent advancements in the synthesis strategies, antibacterial efficacy against Gram-negative bacteria, underlying antimicrobial mechanisms, and biomedical applications of four main carbon nanomaterials (CNMs) of graphene quantum dots (GQDs), carbon dots (CDs), carbon nanotubes (CNTs), and graphene. The preparation methods and antibacterial mechanisms of CNMs with antibacterial properties are the main section. Additionally, the review addresses the current challenges hindering their clinical translation and explores potential future directions with a focus on efficacy and safety. By collating current findings, this review aims to establish a theoretical foundation for the development of innovative antimicrobial agents targeting Gram-negative bacteria.

Identifiers

PMID40599578
PMCPMC12207859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.